The Arora Report

Rss Facebook Twitter Linkedin

Stock Market News To Give You An Edge

Proven Track Record of Most Accurate Analysis

Stock Market News
To Give You An Edge​

Proven Track Record
of Most Accurate Analysis

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

COMPLETELY INDEPENDENT AND OBJECTIVE

The Arora Report, Ltd. is a rare publisher that does not accept advertisements. This way The Arora Report can not be influenced. The Arora Report also does not accept payments from any company that is the subject of the posts. The Arora Report has forsaken millions of dollars in revenues to avoid conflicts of interest. Our sole job is to help you. Read more.

UPDATE ON UNITED THERAPEUTICS $UTHR

September 8, 2017

This post was just published on ZYX Buy Change Alert. UTHR has announced that it will continue the FREEDOM-EV study of Orenitram extended-release tablets. This is good news.  However, many analysts were hoping for better news.  A better news would have been if the effectiveness was so good that there would be no need to continue the study as planned. UTHR remains a takeover target but the probability of a buyout is now lower What To Do Now Those in the stock may consider continuing to hold and change stops to mental stops in the zone of $98 to $108.43.  As the

Read More »

27 HURRICANE STOCKS AND ETFS TO WATCH FOR TRADING AND INVESTING OPPORTUNITIES $UVE $AAL $WGO $HD $LOW $ALL $PGR $GNRC $XLE $OIH $CAR $HTZ $USG

September 8, 2017

My prayers are that Hurricane Irma does not cause much destruction. But, unfortunately, it looks as if it will. For investors, there may be trading opportunities, as shares of some companies may be punished more than they should be. For them, it is important to consider the following three scenarios: • Damage is less than expected • Damage is in line with expectations • Damage is worse than expectations To understand the trading setups, let us start with a chart. The chart Please click here for the chart of Universal Insurance Holdings UVE,  an insurance company that does a lot

Read More »

THE DOW’S FIRST STOP COULD BE 4,000 POINTS LOWER IF THERE’S A REAL SELLOFF $QQQ $AAPL $AMZN $NFLX $FN $GOOG $GOOGL $SPY $NQ_F

September 6, 2017

Prudent investors prepare for different scenarios. Right now, the stock market is assuming two things. First, regarding North Korea, that people in power on all sides are rational. Second, a buy-the-dip mentality will prevail and machines that trade large volumes every day will not make mistakes. To understand that latter scenario, let us look at a very short-term chart and a longer-term chart. Very short-term chart Please click here for the very short-term chart of Nasdaq 100 futures NQU7.  Popular Nasdaq 100 ETF QQQ traced a similar chart. I picked the Nasdaq 100 because it contains popular FAANG stocks such

Read More »

127TH BUYOUT OF AN ARORA REPORT PORTFOLIO STOCK, ROCKWELL COLLINS GETS $140 BUYOUT OFFER, WHAT TO DO NOW $COL $UTX

September 5, 2017

This post was just published on ZYX Buy Change Alert. COL has received $140 buyout offer from UTX.  $93.33 will be paid in cash and $46.67 will be in shares of  UTX based on closing UTX share price of $115.69. The stock is not trading at $140 because there is concern about approval of various governments.  The conference call from UTX is not as positive as it could have been.  This is causing UTX stock to fall. Please note that there is 7.5% collar on the stock portion of the buyout offer.  In plain English this means that even if UTX stock continues

Read More »

WEEKLY MARKET DIGEST: TAX REFORM POSITIVE FOR STOCKS, GOLD HAS A SHOT AT $1400, HARVEY AFTERMATH $DIA $GLD $QQQ $SLV $SPY $TBF $TBT $USO

September 2, 2017

Weekly Digest from The Arora Report is popular among serious investors and money managers because they have found studying insights from the prior week gives them an edge over the coming weeks. Here is the day by day rundown from the morning capsules made available every morning before the market open in the Real Time Feeds to the paying subscribers of The Arora Report.  Please scroll down for the section What To Do Now. THIN TRADING GETTING THINNER, POSITIVE ECONOMIC DATA, TAX REFORM, OUR OFFICE CLOSED TOMORROW FOR LABOR DAY August 31, 2017 This is what you need to know

Read More »

‘95% OFF’ LABOR DAY SALE

August 31, 2017

Labor Day is upon us.  Most investment services are running huge Labor Day sales to attract investors.  Some are offering 95% off. If huge sales were not enough, many investment services are trying to create urgency among investors.  Some are claiming that the market is about to crash and that is the reason for investors to subscribe.  Others are claiming that they have uncovered stocks and somehow investors need to buy them right now. We have received a large number of inquiries from investors asking about a Labor Day sale to subscribe to one of The Arora Report services. The

Read More »

INVESTORS OUGHT TO GET AHEAD OF TRUMP’S TAX-REFORM PUSH $SPY $AMZN $LUV $AAPL $MSFT $GOOG $SCHW $DGX $CVS $CSCO $WDC $CAT $PFE $RL $PAYX

August 28, 2017

President Trump’s economic adviser, Gary Cohn, said that starting this week the administration expects to launch a tax campaign that will lead to major legislation by the end of 2017. That would have major implications for investors, and you should consider trying to get ahead of it. To be prepared to act on what may transpire, investors ought to first look at a simple chart. The chart Please click here to see the chart of SPDR S&P 500 ETF SPY.  Late August to October is historically the weakest seasonal period for the stock market. Going into the weak seasonal period,

Read More »

INTELLIGENCE: CONGRATULATIONS TO THOSE WHO BOUGHT BIOTECH FIRM KITE PHARMA, $180 BUYOUT OFFER $KITE $GILD

August 28, 2017

This post was just published on ZYX Buy Change Alert.   KITE is a biotech firm focused on cancer using engineered T-cell therapy.  When The Arora Report had provided intelligence on KITE it was trading around $54.27.  Now GILD is buying it at $180.  If holding, consider taking profits and exiting the position. Trades posted on The Arora Report Market Blog have produced unrivalled performance since 2007.  Please click here and scroll down to see the table of all trades.  These trades have been scrutinized in real-time by thousands of investors across the globe.  This provides easy verification of performance for newcomers

Read More »

9 Winners. 9 Losers. Gold, Silver & AI Trade Zones.

9 Winners. 9 Losers.
Gold, Silver & AI Trade Zones.

A new market cycle is forming.

AI, Metals &
Memory Playbook

See where sophisticated investors are positioning across software, precious metals, and AI memory.

AI is power hungry. Investors will make a fortune from nuclear power for AI.
Get the list of 12 nuclear power stocks to grab your share of the profits.

Skip to content